company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6288000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6288000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6288000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1948000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10463000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6123000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,22000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,22000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6101000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-588000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5513000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5513000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1798000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7311000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.18
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.18
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3358172.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q2,2012-04-01,2012-06-30,2013-09-05 16:30:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.18
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1580000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9798000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11378000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5110000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,13000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5097000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-452000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4645000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4645000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,-1798000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2847000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.83
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.83
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3439105.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2012.0,Q3,2012-07-01,2012-09-30,2013-11-07 17:08:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.83
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1852000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11462000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13314000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7046000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,8000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,8000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7038000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,190000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7228000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7228000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1797000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9025000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3658016.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q1,2013-01-01,2013-03-31,2014-05-09 16:02:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1836000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12958000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14794000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8526000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,5000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,5000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8521000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,99000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8620000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8620000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,1798000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10418000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,3700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.8
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,3700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.8
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,3722963.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:12:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.8
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6268000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2534000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14803000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17337000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11069000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,13000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11056000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,121000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11177000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11177000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,567000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11744000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22744486.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.52
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22744486.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.52
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q3,2013-07-01,2013-09-30,2014-11-07 16:06:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.52
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6744000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6744000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6744000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3707000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15279000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18986000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12242000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,29000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,29000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12213000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,169000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12382000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12382000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12382000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,15400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.96
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,15400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.96
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,15415373.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.96
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3288000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17407000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20695000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12284000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,36000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,36000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12248000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12248000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12248000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12248000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31394563.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:16:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8411000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4165000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22576000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26741000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18330000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,34000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,34000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18296000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18296000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18296000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18296000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33900000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33900000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33602472.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:08:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33900000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33900000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,33900000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5166000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25526000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30692000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3208000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,48000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,48000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3256000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-448000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3704000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3704000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3704000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34495076.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.11
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36592683.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q3,2014-07-01,2014-09-30,2015-11-06 16:36:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.11
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14636000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14636000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14636000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6501000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34862000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41363000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26727000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,85000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,85000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26642000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.77
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.76
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33667024.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.77
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,34202000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,34202000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,34202000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6954000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,32443000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39397000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5195000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,238000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,238000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4957000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4957000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4957000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4957000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37214747.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q1,2015-01-01,2015-03-31,2016-05-09 08:06:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13219000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13219000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13219000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8929000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36423000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45352000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-32133000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,236000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,236000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31897000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-31897000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-31897000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-31897000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37329220.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q2,2015-04-01,2015-06-30,2016-08-08 16:44:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5480000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5480000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5480000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9927000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36028000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45955000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-40475000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,218000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,218000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40257000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40257000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40257000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40257000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.07
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.07
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37507298.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:13:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.07
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6218000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6218000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6218000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10182000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,36933000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,47115000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-40897000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,276000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,276000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40621000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40621000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40621000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40621000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,37400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.1
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,37400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.1
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37429262.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.1
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31281000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31281000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31281000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10837000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,44038000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,54875000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23594000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,396000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,396000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38000000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.61
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38000000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.61
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37864084.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 11:58:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.61
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6978000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6978000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6978000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12644000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,50804000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,63448000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-56470000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,517000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,517000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-55953000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-55953000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-55953000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-55953000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,37956383.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 13:47:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.47
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8985000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8985000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8985000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11854000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,60643000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,72497000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-63512000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,678000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,678000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-62834000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-62834000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-62834000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-62834000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38548153.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q3,2016-07-01,2016-09-30,2017-11-01 10:44:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22648000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22648000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22648000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15379000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,64678000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,80057000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-57409000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,923000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,923000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-56486000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-56486000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-56486000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-56486000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,39100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.36
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,39100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.36
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,39126400.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.36
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10508000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10508000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10508000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14823000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,62732000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,77555000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-67047000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,881000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,881000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-66166000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-66166000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-66166000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-66166000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.56
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.56
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42280525.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q1,2017-01-01,2017-03-31,2018-05-04 12:10:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.56
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11346000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11346000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11346000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16130000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,79816000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,95946000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-84600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1518000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1518000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-83082000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-83082000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-83082000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-83082000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.78
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.78
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46745760.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 09:02:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.78
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11358000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11358000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11358000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17458000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,72917000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,90375000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-79017000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1880000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1880000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-77137000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-77137000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-77137000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-77137000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,48500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,48459424.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q3,2017-07-01,2017-09-30,2018-11-01 09:33:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9799000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9799000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9799000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22713000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,77216000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,99929000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-90130000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1845000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1845000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-88285000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-88285000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-88285000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-88285000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.82
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,46600000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.82
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,46587631.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.82
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8762000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8762000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8762000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,24550000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,78224000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,102774000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-94012000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3187000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3187000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-90825000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-90825000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-90825000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-90825000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,55700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,55700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,55694603.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 08:57:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,40414000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,40414000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,40414000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26633000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,86730000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,113363000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-72949000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4204000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4204000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-68745000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-68745000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-68745000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-68745000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,57800000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.19
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,57800000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.19
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,57721786.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 08:56:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.19
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15198000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,695000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,695000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14503000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31104000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,82561000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,113665000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-99162000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4498000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4498000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-94664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-94664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-94664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-94664000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58100000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58033386.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q3,2018-07-01,2018-09-30,2019-10-31 09:14:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.63
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30013000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30013000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,702000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,702000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29311000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31858000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,93809000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,125667000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-96356000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4562000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4562000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-91794000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-91794000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-91794000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-91794000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,57400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.58
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,57400000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.58
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,57418300.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.58
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30227000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30227000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,334000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,334000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29893000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31791000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,95585000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,127376000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-97483000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,4405000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4405000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-93078000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-93078000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-93078000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-93078000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58500000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58453918.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q1,2019-01-01,2019-03-31,2020-04-30 09:47:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26221000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26221000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,303000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,303000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25918000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,32390000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,107389000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,139779000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-113861000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3990000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3990000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-109871000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-109871000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-109871000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-109871000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58800000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.87
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58800000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.87
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58722244.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 08:56:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.87
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,26024000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,26024000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,393000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,393000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25631000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,33019000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,101672000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,134691000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-109060000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2887000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2887000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-106173000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-106173000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-106173000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-106173000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.81
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58700000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.81
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58803534.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q3,2019-07-01,2019-09-30,2019-10-31 09:14:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.81
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,35440000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,35440000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,287000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,287000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35153000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34834000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,106248000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,141082000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-105929000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3579000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3579000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-102350000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-102350000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-102350000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-102350000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,60000000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,60000000.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.59
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59994539.0
Agios Pharmaceuticals Inc,AGIO,,0001439222,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.59
